DDInter469 DDInter1628
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Dalfopristin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} (Compound) upregulates {v} (Gene) AKAP8L
AKAP8L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Loratadine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Loratadine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} (Compound) downregulates {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) upregulates AKAP8L (Gene) and AKAP8L (Gene) is upregulated by Ruxolitinib (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) downregulates SMNDC1 (Gene) and SMNDC1 (Gene) is upregulated by Ruxolitinib (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)